Business
-
US biotech Diomics Corporation has announced plans to develop a prophylactic nasal spray against COVID-19 using antibodies licensed from Active Motif. According to the company, the Dioguard nasal spray, currently in in vitro testing, uses… Read more . . .
-
Savara has discontinued development of Molgradex inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of nontuberculous mycobacterial (NTM) lung infection and will not restart the Phase 2a ENCORE study of Molgradex for NTM… Read more . . .
-
Swedish DPI company Iconovo said that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance regarding a patent covering Iconovo’s ICOres reservoir-based dry powder inhaler. The patent, titled “Dry Powder… Read more . . .
-
H&T Presspart and Hovione Technology have revealed their collaboration with Bilim Pharmaceuticals on a dry powder inhaler based on the PowdAir Plus device. H&T Presspart acquired global rights to the capsule based DPI device from Hovione… Read more . . .
-
Virpax Pharmaceuticals said that it has acquired exclusive North American rights to Nanomerics’ MMS019 nasal powder, which it calls a “high density molecular masking spray” and which is intended to block viruses from taking hold in… Read more . . .
-
Medical Developments International (MVP) has announced that it will buy back the European Union rights to its Penthrox methoxyflurane inhaler from Mundipharma for €3 million, plus a 5% royalty up to a maximum of €5… Read more . . .
-
According to Lannett, the company has signed an agreement with Chinese inhaled drug developer Respirent for exclusive rights to distribute Respirent’s generic version of GSK’s Flovent Diskus fluticasone propionate DPI, which is in early development.… Read more . . .
-
Danish pharma company Union Therapeutics has entered into an agreement with TFF Pharmaceuticals for an option to license TFF’s dry powder niclosamide, the companies announced. The deal includes potential inhaled and oral formulations of niclosamide… Read more . . .
-
AstraZeneca has announced that the first doses of its FluMist Quadrivalent live intranasal flu vaccine for the 2020-2021 US influenza season have shipped. FluMist Quadrivalent is approved for use in children over the age of… Read more . . .
-
TFF Pharmaceuticals announced that the company has raised $25.9 million in a private placement, with the funds to be used to “to accelerate the expansion of the company’s internal development portfolio beyond its programs for… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
May 30-June 2: ISAM Congress 2027, Dublin, Ireland
June 23: SMI London, London, UK

